Evidence map›Paper›PMID 26867643›Full record

ArticleArthritis research & therapy2016

PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus.

Qing Luo, Zikun Huang, Jianqing Ye, Yating Deng, Le Fang, Xue Li, Yang Guo, Hong Jiang, Beihua Ju, Qingshui Huang and 1 more

Abstract read
In one paragraph

Article in Arthritis research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Engineered bacteria reprogram tumor microenvironmentActa pharmaceutica Sinica. B · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Effects of immune exhaustion and senescence of innate immunity in autoimmune disorders.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Review
  13. Article
  14. When AHR signaling pathways meet viral infections.Cell communication and signaling : CCS · 2023
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Increased TIGITExperimental and therapeutic medicine · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qing LuoDepartment of Clinical Laboratory, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China. lxc042@163.com.
Zikun HuangDepartment of Clinical Laboratory, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China. 491353062@qq.com.
Jianqing YeDepartment of medical college, Nanchang University, Nanchang, Jiangxi, 330006, China. 1239793880@qq.com.
Yating DengDepartment of medical college, Nanchang University, Nanchang, Jiangxi, 330006, China. 765840652@qq.com.
Le FangDepartment of Blood Transfusion, 521 Hospital of Ordnance Industry, Xi'an, Shanxi, 710065, China. 289278162@qq.com.
Xue LiDepartment of medical college, Nanchang University, Nanchang, Jiangxi, 330006, China. 313865025@qq.com.
Yang GuoDepartment of medical college, Nanchang University, Nanchang, Jiangxi, 330006, China. 839444295@qq.com.
Hong JiangDepartment of medical college, Nanchang University, Nanchang, Jiangxi, 330006, China. 602422908@qq.com.
Beihua JuDepartment of Clinical Laboratory, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China. 276736686@qq.com.
Qingshui HuangDepartment of Clinical Laboratory, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China. hqsdoctor@163.com.
Junming LiDepartment of Clinical Laboratory, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China. lisir361@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is well-known that increased frequency of neutrophils was found in patients with systemic lupus erythematosus (SLE). However, the immunomodulatory roles and mechanisms of neutrophils in SLE are poorly understood.

methodsPatients with SLE were recruited from the First Affiliated Hospital of Nanchang University. The medical history, clinical manifestations, physical examination, laboratory measurements, therapeutic regimen and treatment response were recorded. The expression of costimulatory molecules including programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), CD40, T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory domains (TIGIT), CD80 and CD86 on neutrophils were determined by flow cytometry. The frequencies of PD-L1-expressing neutrophils in patients with SLE were further analyzed for their correlation with markers of autoimmune response, inflammation, disease activity and severity of SLE.

resultsThe frequency of PD-L1-expressing neutrophils was significantly elevated in SLE patients compared to the healthy controls (P < 0.0001). The frequency of PD-L1-expressing neutrophils in patients with SLE was increased significantly in subjects with high ANA titre, high anti-nRNP/Sm, high levels of inflammatory markers and high SLE Disease Activity Index (SLEDAI) score. Furthermore, the percentages of PD-L1-expressing neutrophils were significantly decreased in SLE patients that received a 15-day regular treatment with corticosteroids and immunosuppressive drugs (P = 0.0075).

conclusionThe frequency of PD-L1-expressing neutrophils is elevates in patients with SLE, correlates with the disease activity and severity of SLE, and may serves as a negative feedback mechanism preventing potential tissue damage caused by excessive autoimmune responses in patients with SLE.

Indexed as

Disease ProgressionSeverity of Illness IndexAdultB7-H1 AntigenBiomarkersFemaleGene Expression RegulationHumansLupus Erythematosus, SystemicMaleMiddle AgedNeutrophilsYoung AdultB7-H1 AntigenBiomarkersCD274 protein, human

Identifiers

PMID26867643
PMCPMC4751645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.